Compounds > debrisoquin

debrisoquin and 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol

debrisoquin has been researched along with 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bertilsson, L; Dahl, ML; Ekqvist, B; Llerena, A2

Other Studies

2 other study(ies) available for debrisoquin and 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol

ArticleYear
Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers.
    Therapeutic drug monitoring, 1992, Volume: 14, Issue:3

    Topics: Chromatography, High Pressure Liquid; Debrisoquin; Haloperidol; Humans; Hydroxylation; Oxidation-Reduction; Phenotype

1992
Genetic factors in the metabolism of haloperidol.
    Clinical neuropharmacology, 1992, Volume: 15 Suppl 1 Pt A

    Topics: Debrisoquin; Half-Life; Haloperidol; Humans; Hydroxylation; Phenotype

1992